Gilles Salles
吉尔·萨莱斯
MD, PhD
Chief, Lymphoma Service; Attending Physician淋巴瘤科主任；主治医师
👥Biography 个人简介
Gilles Salles, MD, PhD is Chief of the Lymphoma Service at Memorial Sloan Kettering Cancer Center. Previously at Hospices Civils de Lyon, he is internationally recognized for pioneering clinical development of bispecific antibodies—including mosunetuzumab, glofitamab, and loncastuximab—in relapsed/refractory B cell lymphomas.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Bispecific Antibody Development in DLBCL
Led pivotal trials of CD20xCD3 bispecific antibodies (mosunetuzumab, glofitamab) and CD19-targeted ADC loncastuximab, establishing new treatment options for heavily pre-treated DLBCL and follicular lymphoma.
International Lymphoma Research Leadership
Serves on ESMO, EHA, and ASH lymphoma committees; led European Mantle Cell Lymphoma Network and Global Lymphoma Alliance initiatives to harmonize treatment guidelines.
Representative Works 代表性著作
Mosunetuzumab in Relapsed or Refractory Follicular Lymphoma
New England Journal of Medicine (2022)
Pivotal study demonstrating durable complete responses with mosunetuzumab, a CD20xCD3 T cell-engaging bispecific antibody, in follicular lymphoma.
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
New England Journal of Medicine (2023)
Phase II trial reporting high complete response rates with glofitamab in multiply relapsed DLBCL, leading to accelerated FDA approval.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 吉尔·萨莱斯 的研究动态
Follow Gilles Salles's research updates
留下邮箱，当我们发布与 Gilles Salles（Memorial Sloan Kettering Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment